Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry
Authors:
- Lucas V A BoersmaLBLucas V A Boersma
- Gábor SzéplakiGSGábor Széplaki
- Antonio Dello RussoARAntonio Dello Russo
- Ignacio García-BolaoIGIgnacio García-Bolao
- Nándor SzegediNSNándor Szegedi
- Stephan WillemsSWStephan Willems
- Haris HaqqaniHHHaris Haqqani
- Estelle GandjbakhchEGEstelle Gandjbakhch
- Francesco SolimeneFSFrancesco Solimene
- George AndrikopoulosGAGeorge Andrikopoulos
Top Cited Papers
Open Access
- 1 September 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Abstract
Aims: Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years. Methods and results: FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). Pulmonary vein isolation (PVI)-only procedures were performed in 80.8% of paroxysmal vs. 57.5% for non-paroxysmal patients (P < 0.01). Median procedure, left atrial dwell, and fluoroscopy times were 51[40–70], 31[24–41], and 12[8–17] min, respectively. The rate of early onset serious adverse events was 1.5% and did not differ by ablation strategy or AF indication. At 1-year, clinical effectiveness was 80.8% for paroxysmal AF and 67.7% for non-paroxysmal AF, with no difference within indication by lesion set (paroxysmal: 81.2% PVI-only vs. 79.0% PVI+, P = 0.65; non-paroxysmal: 67.5% PVI-only vs. 67.7% PVI+, P = 0.79). Acute results reinforce a short procedural learning curve with no difference in 1-year effectiveness by operator experience. Conclusion: The FARADISE registry provides a snapshot of real-world clinical use of the pentaspline PFA catheter. Acute results demonstrate favourable procedural and safety outcomes regardless of AF indication. One-year outcomes are encouraging, with no differences seen within indication based on ablation strategy.Keywords
Funding Information
- Boston Scientific
This publication has 36 references indexed in Scilit:
- 5S Study: Safe and Simple Single Shot Pulmonary Vein Isolation With Pulsed Field Ablation Using SedationCirculation: Arrhythmia and Electrophysiology, 2022
- Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF)EP Europace, 2022
- Worldwide sedation strategies for atrial fibrillation ablation: current status and evolution over the last decadeEP Europace, 2021
- Cryoablation or Drug Therapy for Initial Treatment of Atrial FibrillationNew England Journal of Medicine, 2021
- Cryoballoon Ablation as Initial Therapy for Atrial FibrillationNew England Journal of Medicine, 2021
- Safety and efficacy of cryoballoon ablation for the treatment of paroxysmal and persistent AF in a real‐world global setting: Results from the Cryo AF Global RegistryJournal of Arrhythmia, 2021
- Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST)EP Europace, 2020
- Pulsed Field Ablation in Patients With Persistent Atrial FibrillationJACC, 2020
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJACC, 2019
- Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registryEuropean Heart Journal, 2017